Celltrion Is Latest To File Eylea Rival In US

Korean Firm Submits Application For CT-P42 Aflibercept Biosimilar To US FDA

 
• By Dave Wallace

Celltrion has become the latest firm to reveal that it has filed a biosimilar Eylea application with the US FDA in the form of its CT-P42 aflibercept candidate.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
Celltrion has submitted its Eylea biosimilar to the FDA • Source: Shutterstock

More from Biosimilars

More from Products